CME Group insider trading
Every open-market purchase and sale by CME Group's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following CME Group’s insiders pay?
From February 18, 2010 to October 27, 2026, 49 insiders reported 33 open-market purchases and 284 sales not made under a pre-set plan in CME Group. Twelve months after each purchase was reported, the shares were −3.3% against the S&P 500 on average (median −4.0%), over 29 purchases with a full year of prices; 35% beat the index. After sales, the shares moved +0.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 16, 2010 into $40,836 by November 2, 2026, +9.1% a year. It held shares 66% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $52,282 (+10.8% a year), and held throughout $93,035 (+14.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Gepsman Martin J | Director | 0 | — | — | 31 | +3.4% (29) | October 22, 2026 |
| Duffy Terrence A | Chairman and CEO | 3 | −3.1% (3) | 0% | 22 | +2.6% (19) | September 11, 2026 |
| Shepard William R | Director | 23 | −3.0% (19) | 37% | 0 | — | September 28, 2026 |
| Odom C C II | Director | 0 | — | — | 18 | −5.1% (18) | May 22, 2014 |
| Pankau Ronald A. | Director | 0 | — | — | 17 | +6.0% (17) | February 28, 2020 |
| Sammann Derek | Sr MD Gl Hd Commodities Mkts | 0 | — | — | 17 | +1.0% (16) | November 21, 2025 |
| Cronin Kathleen M | Sr MD Gen Counsel & Corp Secr | 0 | — | — | 14 | +3.5% (14) | March 14, 2022 |
| Suskind Dennis | Director | 0 | — | — | 13 | +2.0% (12) | February 9, 2026 |
| Cook Elizabeth A | Director | 0 | — | — | 10 | −6.4% (8) | September 14, 2026 |
| Winkler Julie | Sr MD Chief Commercial Officer | 0 | — | — | 10 | +0.3% (10) | February 14, 2025 |
| Carey Charles P | Director | 0 | — | — | 9 | −4.9% (9) | June 11, 2025 |
| Holzrichter Julie | Sr MD Chief Operating Officer | 0 | — | — | 9 | +7.2% (9) | August 15, 2023 |
| Kometer Kevin | Sr MD Chief Information Office | 0 | — | — | 9 | +8.1% (9) | February 14, 2022 |
| Bitsberger Timothy S. | Director | 0 | — | — | 8 | −1.5% (8) | October 30, 2024 |
| Durkin Bryan T | President | 0 | — | — | 8 | +5.8% (7) | February 23, 2026 |
| Piell Hilda Harris | Sr MD & Chief HR Officer | 0 | — | — | 8 | +3.8% (7) | May 19, 2026 |
| Cutinho Sunil | Chief Information Officer | 0 | — | — | 7 | −14.4% (6) | October 27, 2026 |
| Glickman Daniel R | Director | 0 | — | — | 7 | −5.6% (7) | June 7, 2024 |
| Katler Gary M | Director | 0 | — | — | 6 | +8.4% (6) | February 11, 2013 |
| Tully Sean | Sr MD Global Hd Financial & OT | 0 | — | — | 6 | −9.0% (6) | March 14, 2022 |
| Vroman Ken | Chief Transformation Officer | 0 | — | — | 6 | +4.6% (5) | March 12, 2026 |
| Bernacchi Jeffrey M. | Director | 0 | — | — | 5 | +12.8% (5) | February 27, 2019 |
| Corvino Robert F | Director | 0 | — | — | 5 | −15.4% (5) | May 5, 2011 |
| Donaldson James A | Director | 0 | — | — | 4 | −5.1% (4) | November 15, 2013 |
| Gerdes Larry G | Director | 3 | +0.3% (3) | 67% | 1 | −21.4% (1) | April 28, 2025 |
| Mccourt Timothy Francis | Sr MD Global Head Equity & FX | 0 | — | — | 4 | −4.5% (4) | September 17, 2025 |
| Pietrowicz John W. | Sr MD Chief Financial Officer | 0 | — | — | 4 | +19.0% (4) | November 3, 2017 |
| Siegel Howard J | Director | 0 | — | — | 4 | −8.0% (4) | March 17, 2025 |
| Gill Phupinder | CEO | 1 | −8.5% (1) | 0% | 2 | +5.0% (2) | August 5, 2015 |
| Rich Linda Dallas | Sr MD Govt Rel Legisl Affairs | 0 | — | — | 2 | −9.3% (2) | November 26, 2013 |
| Sprague Suzanne | COO & Global Head of Clearing | 0 | — | — | 2 | −6.9% (2) | March 4, 2025 |
| Zagotta Robert | Sr MD Strategy & Execution | 0 | — | — | 2 | +17.6% (2) | June 7, 2016 |
| Clegg Jackie M | Director | 0 | — | — | 1 | −0.7% (1) | December 17, 2013 |
| Fitzpatrick Lynne | Sr MD Chief Financial Officer | 0 | — | — | 1 | +5.5% (1) | September 17, 2024 |
| Ford Harold Eugene JR. | Director | 0 | — | — | 1 | — | November 4, 2025 |
| Kaye Daniel G | Director | 0 | — | — | 1 | −27.8% (1) | May 23, 2025 |
| Lockett Phyllis M | Director | 0 | — | — | 1 | −22.1% (1) | May 20, 2025 |
| Lucas Deborah J | Director | 0 | — | — | 1 | +4.2% (1) | March 18, 2025 |
| Melamed Leo | Director | 0 | — | — | 1 | +11.8% (1) | February 7, 2018 |
| Newsome James E | Director | 0 | — | — | 1 | −25.3% (1) | June 16, 2010 |
When several insiders traded CME Group
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of CME Group in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −3.3% against the index. After 18 selling crowds, +1.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 28, 2025 | 3 selling | +16.2% | −20.2% | not yet |
| March 31, 2025 | 7 selling | −6.4% | −17.0% | −2.3% |
| October 31, 2024 | 5 selling | +4.6% | +31.1% | +4.0% |
| May 31, 2024 | 5 selling | −0.3% | +3.6% | +28.8% |
| August 31, 2023 | 7 selling | +6.6% | −1.5% | −14.4% |
| December 30, 2022 | 2 buying | +6.0% | −6.1% | +1.1% |
| September 30, 2022 | 4 selling | −9.5% | −4.4% | −0.3% |
| November 30, 2021 | 6 selling | +12.9% | +2.0% | −8.1% |
| December 31, 2020 | 4 selling | +5.4% | +1.5% | +0.7% |
| August 31, 2020 | 4 selling | −4.0% | +9.7% | −12.8% |
| December 31, 2019 | 3 selling | +6.2% | −12.6% | −26.2% |
| December 29, 2017 | 4 selling | +12.3% | +10.5% | +34.8% |